VAXIMM AG Employee Directory

Biotechnology ResearchBasel-stadt, Switzerland2-10 Employees

VAXIMM AG is a biotechnology company focused on developing oral T-cell immunotherapies for cancer. Its approach relies on a live attenuated bacterial vaccine strain, engineered to stimulate cytotoxic T-cells to target tumor structures, with a pipeline of development candidates aimed at different tumor targets. The lead product, VXM01, is designed to activate killer cells against tumor vasculature and immune-suppressive cells, potentially improving immune cell infiltration in solid tumors, and has progressed in clinical development for multiple tumor types, including brain cancer. The company also collaborates with external partners, such as Merck KGaA on a trial combining VXM01 with avelumab, and has a separate agreement with CMS granting rights to its programs in China and other Asian markets. Based in Basel, Switzerland, VAXIMM operates a development-focused subsidiary in Mannheim, Germany, and maintains a corporate footprint in the Swiss/German biotechnology landscape.

Sign up for free to view info

Company overview Email format